ZidovudineThird Party Manufacturing in India

Zidovudine works by selectively interfering with the replication mechanism of the HIV virus, halting the production of new viral DNA.

Once inside the host cell, Zidovudine is activated by cellular kinases into zidovudine triphosphate. As a structural analog of thymidine, it competes with natural nucleotides to bind to the viral enzyme reverse transcriptase. Because Zidovudine lacks the crucial 3'-hydroxyl group required to attach the next nucleotide, its incorporation causes premature chain termination, effectively stopping the synthesis of viral DNA.

Unlike traditional antivirals, Zidovudine has a higher affinity for viral reverse transcriptase than for human DNA polymerases. It is a cornerstone in highly active antiretroviral therapy (HAART) and is essential for reducing viral loads and boosting immune function.

Therapeutic Uses

Zidovudine is prescribed for the treatment of:

• HIV-1 Infection: Used in combination with other antiretroviral agents to suppress viral replication and increase CD4 cell counts.
• Prevention of Perinatal Transmission: Administered to pregnant women and newborns to significantly reduce the risk of mother-to-child HIV transmission.
• Post-Exposure Prophylaxis (PEP): Part of combination regimens given after potential occupational or non-occupational exposure to HIV.

Why Manufacturers Choose Zidovudine

Zidovudine is a critical molecule in the global fight against HIV/AIDS, featured prominently on the WHO Model List of Essential Medicines. Indian pharmaceutical manufacturers are the backbone of global antiretroviral supply, providing high-quality, affordable formulations to international health organizations and developing nations.

This makes Zidovudine one of the most sought-after antiretroviral agents for third party manufacturing in India, driven by continuous institutional procurement and robust export demand.